In BC hormone receptor-positive subtypes there has been detected higher levels of Ubc9 with respect to hormone receptor-negative and invasive BC lesions, and in metastatic BC, Ubc9 expression is decreased in comparison to the corresponding normal breast or primary BC (Moschos et al., 2010). Here, UBE2I is linked to breast cancer.